^
Association details:
| Biomarker: | BRAF mutation + RAS mutation |
|---|---|
| Cancer: | Chronic Lymphocytic Leukemia |
| Drug: | Imbruvica (ibrutinib) (BTK inhibitor) + Rituxan (rituximab) (CD20 inhibitor) + Gazyva (obinutuzumab) (CD20 inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
345 Genetic Markers and Front Line FCR/BR Vs. Rve, Gve and Give Treatment – Outcome Results from the CLL13/GAIA Trial
Published date:
11/03/2022
Excerpt:
In the combined analysis for RVe/GVe/GIVe U-IGHV (HR 2.29, p<0.01), mutations in NOTCH1 (HR 1.76, p<0.01) and BRAF/RAS (HR 2.45, p<0.01) were associated with significantly shorter PFS and del(13q) (HR 0.67, p=0.03) with longer PFS.
DOI:
https://doi.org/10.1182/blood-2022-163775
Trial ID:
